BAFFR-CAR T cell therapy (PeproMene Bio)

N/A

Report date: 2025/06/19 17:22:33

Base Information

Drug NameBAFFR-CAR T cell therapy (PeproMene Bio)
Drug Alias NamePMB-101PMB-CT01
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-cell activating factor receptor modulators
TargetsB-cell activating factor receptor
Therapy Area/IndicationsLymphoma, FollicularLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPeproMene Bio IncCity Of Hope National Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesCity Of Hope National Medical CenterPeproMene Bio Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, FollicularLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A